Administration of agents for the treatment of inflammation
AssigneeBiogen MA Inc.
InventorsJulie Taylor, Theodore A. Yednock
Life of this patent
Estimating the term…
Abstract
A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.
Claims7
A method of monitoring a chronic administration regimen for treating pathological inflammation in a subject, wherein the pathological inflammation is modulated by an alpha-4 integrin, comprising chronically administering 300 mg natalizumab or an immunologically active fragment thereof by infusion every four weeks to the patient for a period of at least six months;
- and detecting levels of brain lesions using an imaging technique.
Dependencies are inferred from the claim text.